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Basal cell carcinoma (BCC) is the most common
form of skin cancer, making up approximately 80%
of all nonmelanoma skin cancers.1 Traditional ther-
apy includes various types of surgery (Mohs, cryo-
surgery, excision, electrodessication and curettage),
topical therapies (5-fluorouracil, imiquimod), or ra-
diation therapy. A new and effective treatment,
vismodegib, became available recently. The mecha-
nism of action of vismodegib is based on inhibition
of the Hedgehog pathway, which is responsible for
cell growth in more than 90% of BCC cases.2
Response rates of 30% in metastatic disease and
43% in locally advanced disease, with complete
response in half the patients with locally advanced
disease, have been reported.3
Despite the large amount of data concerning
response rate and response duration of this Hedge-
hog signaling pathwayetargeting agent, there is no
published information about time to response. This
information is often requested by patients before
treatment commences. The current case of locally
advanced BCC, which responded quickly to treat-
ment with vismodegib and showed signs of wound
healing at the first assessment after 4 weeks, repre-
sents the type of information that patients request
before treatment initiation.CASE REPORT
A 45-year old man presented with a large, 7-3 13-
cm, ulcerated lesion on his forehead, with extension
to the left fronto-parietal region (Fig 1, A). The lesion
had progressed over 8 years and had never been
treated. Biopsy results showed BCC with keratotic
differentiation. There was no history of family-
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computed tomography scan found involvement of
the underlying bones but no signs of distant spread.
The patient was started on treatment with vismo-
degib on 15 October 2013 at a standard dose of
150 mg once daily. On evaluation 4 weeks later, there
was remarkable improvement, with a visible decrease
in tumor size, signs of healing in the periphery (Fig 1,
B), and minimal side effects, including grade 1 hair
loss and fatigue.
Four months after treatment initiation, the patient
experienced complete clinical response with a well-
healed scar and small regions of residual crusts in the
region where the giant tumor ulcer had previously
persisted (Fig 1, C ).
The patient continued the treatment with mild
side effects, all grade 1, including alopecia, de-
creased appetite, muscle spasm, and fatigue, without
any evidence of active disease in the previously
involved area. Although the patient achieved com-
plete clinical remission, it was not confirmed histo-
logically (Fig 1, D). He is still in remission after
18 months of treatment.
DISCUSSION
According to previously published data from the
ERIVANCE phase II trial, the most robust source for
accurate information regarding drug efficacy and
common adverse events, the first clinical evaluation
of patients was conducted at 8 weeks of therapy, and
most patients exhibited some degree of tumorJAAD Case Reports 2015;1:267-8.
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Fig 1. A, The lesion at treatment beginning. B, The lesion after 4 weeks of treatment. C, The
lesion after 4 months of treatment. D, Complete clinical response after 8 months of treatment.
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duration, 1.4 to 16.8 months, we learn that some of
the responses accrued very quickly. Common
adverse events observed in studies of vismodegib
are hypothesized to be mechanism related. These
events include muscle spasms (any grade, 68%; grade
3-4, 4%), dysgeusia (any grade, 58%; grade 3-4, 0%),
alopecia (any grade, 63%), fatigue (any grade, 36%;
grade 3-4, 4%), and weight loss (any grade, 46%;
grade 3-4, 5%).3 In a recent publication evaluating the
clinical benefit to patients with locally advanced BCC
in the ERIVANCE trial, 76% had clinical benefit,
significant in 65%. The system of response assessment
based on expert clinical judgment was found to have
a high degree of interpanelist agreement and pro-
vided strong evidence that treatmentwith vismodegib
results in clinically meaningful and durable responses
in patients.4 However, tumor recurrence after treat-
ment cessation was reported in most of the cases.5 In
the most sensitive patient population, those with
basal cell nevus syndrome, all carrying the PTCH1
mutation that predisposes them to developing hun-
dreds of BCCs, a reduction in the number of new
surgically eligible BCC was seen after 1 month of
treatment with vismodegib.6The current case presents a good example of
dramatic response with visible tumor shrinkage and
wound healing in an unusually short period. Most of
the patients with locally advanced BCC are old, and
many fear starting new medications, preferring to
delay treatment initiation. The information that
healing is seen relatively rapidly can help patients
in their decision making.
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